Search results for "Cape"

showing 10 items of 1938 documents

New Perspectives in the Treatment of Advanced Gastric Cancer: S-1 as a Novel Oral 5-FU Therapy in Combination with Cisplatin

2015

Oral fluoropyrimidines have been available for more than 10 years. Capecitabine is well established in treating solid tumors in Europe. S-1 (Teysuno®), an oral formulation containing the 5-fluorouracil (5-FU) prodrug tegafur and the two enzyme modulators gimeracil and oteracil, has not been available in non-Asia countries until recently. In Japan, S-1 in combination with cisplatin is the recommended first-line treatment in patients with gastric cancer. In Europe, the first trials with S-1 were disappointing due to high unacceptable incidences of adverse events. Pharmacokinetic studies showed differences in Asian and Caucasian patients; therefore, a new non-Asian study program was initiated,…

0301 basic medicineOncologymedicine.medical_specialtyAdministration OralAntineoplastic AgentsTegafurCapecitabine03 medical and health sciences0302 clinical medicineStomach NeoplasmsInternal medicineDrug DiscoverymedicineClinical endpointHumansPharmacology (medical)Survival rateNeoplasm StagingPharmacologyCisplatinbusiness.industryCancerGeneral Medicinemedicine.diseaseHematologic DiseasesSurvival Rate030104 developmental biologyInfectious DiseasesOncologyTolerability030220 oncology & carcinogenesisDrug Therapy CombinationFluorouracilCisplatinbusinessmedicine.drugTegafur/gimeracil/oteracilChemotherapy
researchProduct

Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized pha…

2017

Abstract Objectives To determine predictive/prognostic factors for patients with metastatic breast cancer (MBC) receiving first-line monochemotherapy using biomarker analysis and geriatric assessment (GA). Materials and Methods Karnofsky Performance Status (KPS) and GA as clinical parameters, and prognostic inflammatory and nutritional index (PINI), and Glasgow prognostic score (GPS) as biomarkers were analyzed for association with clinical outcome within the randomized phase III PEg-LIposomal Doxorubicin vs. CApecitabin iN MBC (PELICAN) trial of first-line pegylated liposomal doxorubicin (PLD) or capecitabine. Results Of 210 patients, 38% were > 65 years old. GA (n = 152) classified 74% as…

0301 basic medicineOncologymedicine.medical_specialtyMultivariate analysisAnthracyclinemedicine.medical_treatmentBreast NeoplasmsPolyethylene GlycolsCapecitabine03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansDoxorubicinKarnofsky Performance StatusGeriatric AssessmentCapecitabineAgedChemotherapyFrailtybusiness.industryAge FactorsGeriatric assessmentMiddle Agedmedicine.diseaseMetastatic breast cancer030104 developmental biologyTreatment OutcomeOncologyDoxorubicin030220 oncology & carcinogenesisDisease ProgressionBiomarker (medicine)FemaleGeriatrics and GerontologybusinessBiomarkersmedicine.drugJournal of geriatric oncology
researchProduct

Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or…

2016

Background: IMAB362, a chimeric monoclonal antibody that mediates specific killing of cancer cells expressing the tight junction protein Claudin18.2 (CLDN18.2) by activation of immune effector mechanisms, has demonstrated single-agent activity and tolerability in patients ( pts) with heavily pretreated gastric cancer. Methods: Pts with advanced/recurrent gastric and GEJ cancer were centrally evaluated for CLDN18.2 expression by immunohistochemistry (CLAUDETECT® 18.2 Histology Kit). Eligible pts had a CLDN18.2 expression of ≥2+ in ≥40% tumor cells, an ECOG PS of 0–1 and were not eligible for trastuzumab. Pts were randomized 1:1 to first-line EOX (epirubicin 50 mg/m2 and oxaliplatin 130 mg/m2…

0301 basic medicineOncologymedicine.medical_specialtybusiness.industryCancerHematologymedicine.diseaseLoading doseOxaliplatinCapecitabine03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyTolerabilityTrastuzumab030220 oncology & carcinogenesisInternal medicineMedicineAdenocarcinomabusinessEpirubicinmedicine.drugAnnals of Oncology
researchProduct

La réponse immunitaire anti-tumorale dans le cancer du sein : état des lieux et perspectives thérapeutiques

2017

The role of the immune response in breast cancer is now well recognized and increasingly taken in account. The goal of this article is, in the first part, to underline its prognostic impact and to precise the immunosurvelliance, immunoselection and the immunosubversion concepts involved in the control and evasion of breast carcinoma. In the second part, therapeutic strategies for the restauration of anti-tumor immunity are developed. Vaccination strategies and checkpoints inhibitors blockade strategies are discussed as well as the immunogenic death linked to the conventional treatments of breast cancer.

0301 basic medicineOncologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentImmunotherapymedicine.disease3. Good healthPathology and Forensic MedicineBlockadeImmunosurveillanceVaccination03 medical and health sciences030104 developmental biology0302 clinical medicineBreast cancerImmune systemTumor Escape030220 oncology & carcinogenesisInternal medicinemedicineBreast carcinomabusinessAnnales de Pathologie
researchProduct

Correlation between polymorphism of TYMS gene and toxicity response to treatment with 5-fluoruracil and capecitabine

2020

Tumorigenesis is a multiphasic process in which genetic alterations guide the progressive transformation in cancer cells1. In order to evaluate the possible correlation between some gene variants and the risk of the toxicity development onset, two of the polymorphisms of the thymidylate synthase (TYMS), rs34743033 (2R/3R) and rs16430 (DEL/INS) were investigated. We enrolled in our study 47 patients from the Hospital of Sicily. Our preliminary findings suggest that there could be a linkage between the genotypes discussed and the development of the toxicity following the chemotherapy treatment. These results need to be confirmed by further studies, however this short paper offers some initial…

0301 basic medicineOncologymedicine.medical_specialtymedicine.medical_treatmentlcsh:Medicinethymidylate synthasemedicine.disease_causeThymidylate synthaseArticlelcsh:QM1-695CapecitabineCorrelationCancer Genetics Polymorphisms Thymidylate synthase Toxicity03 medical and health sciences0302 clinical medicineInternal medicineGenotypeMedicineOrthopedics and Sports MedicinegeneticsGeneMolecular BiologyCancerChemotherapybiologybusiness.industrylcsh:RtoxicityCell Biologylcsh:Human anatomy030104 developmental biology030220 oncology & carcinogenesisToxicitybiology.proteinNeurology (clinical)businessCarcinogenesispolymorphismsmedicine.drug
researchProduct

The SCOPE of definitive chemoradiotherapy in locally advanced esophageal cancer: what direction for the future?

2016

Exclusive chemoradiotherapy (CRT) delivering 50 Gy over 5 weeks with cisplatin and fluorouracil-based chemotherapy is a cornerstone in locally advanced esophageal cancer or non-operable patients since the results of the pivotal study of US Intergroup RTOG-8501 (1). This trial has successfully demonstrated that some patients with esophageal carcinoma may be long-term survivors so that this treatment is now definitely accepted as curative (2). Nevertheless the prognosis is still very disappointing with a 5-year overall survival rate of approximately 25%. Attempts to improve overall survival by escalating the dose of radiotherapy with concurrent cisplatin and fluorouracil has been assessed in …

0301 basic medicinePulmonary and Respiratory MedicineOncologymedicine.medical_specialtymedicine.medical_treatmentLocally advancedCetuximab[SDV.CAN]Life Sciences [q-bio]/CancerOutcomes[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract[ SDV.CAN ] Life Sciences [q-bio]/CancerIntensity-Modulated Radiotherapy03 medical and health sciences0302 clinical medicineInternal medicineCarcinomaMedicineComputingMilieux_MISCELLANEOUSCapecitabineCisplatinChemotherapybusiness.industryCarcinomaInduction ChemotherapyEsophageal cancermedicine.diseaseRadiation-Therapy3. Good healthRadiation therapyEditorial030104 developmental biologyChemoradiationFluorouracil030220 oncology & carcinogenesisIi Randomized-TrialCisplatinbusiness[ SDV.MHEP.PSR ] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractChemoradiotherapymedicine.drug
researchProduct

Deciphering function of the pulmonary arterial sphincters in loggerhead sea turtles (Caretta caretta)

2018

To provide new insight to the pathophysiological mechanisms underlying gas emboli (GE) in bycaught loggerhead sea turtles (Caretta caretta), the present study investigated the vasoactive characteristics of the pulmonary and systemic arteries, and the lung parenchyma (LP). Tissues were opportunistically excised from recently dead animals for in vitro studies of vasoactive responses to four different neurotransmitters: acetylcholine (ACh, parasympathetic), serotonin (5HT), epinephrine (Epi, sympathetic) and histamine. The significant amount of smooth muscle in the LP contracted in response to ACh, Epi and histamine. The intrapulmonary and systemic arteries contracted under both parasympatheti…

0301 basic medicineSTEADY-STATEmedicine.medical_specialtyPhysiologyGREEN TURTLECAPE FEAR RIVERCARDIAC SHUNTSAquatic ScienceStress03 medical and health scienceschemistry.chemical_compoundInternal medicinemedicine.arteryParenchymamedicineMolecular BiologyEcology Evolution Behavior and SystematicsDecompression sicknessBLOOD-FLOWbusiness.industryDECOMPRESSION-SICKNESSBlood flowBlood flowDiving physiologyVAGAL CONTROL030104 developmental biologymedicine.anatomical_structurechemistryInsect SciencePulmonary arteryPulmonary blood flowCardiologySphincterPulmonary shuntAnimal Science and ZoologySerotoninmedicine.symptomPHYSIOLOGICAL ADJUSTMENTSbusinessAcetylcholineHistamineGAS-EXCHANGENORTH-CAROLINAmedicine.drugJournal of Experimental Biology
researchProduct

Viral replication modes in single-peak fitness landscapes: A dynamical systems analysis

2017

Positive-sense, single-stranded RNA viruses are important pathogens infecting almost all types of organisms. Experimental evidence from distributions of mutations and from viral RNA amplification suggest that these pathogens may follow different RNA replication modes, ranging from the stamping machine replication (SMR) to the geometric replication (GR) mode. Although previous theoretical work has focused on the evolutionary dynamics of RNA viruses amplifying their genomes with different strategies, little is known in terms of the bifurcations and transitions involving the so-called error threshold (mutation-induced dominance of mutants) and lethal mutagenesis (extinction of all sequences du…

0301 basic medicineStatistics and ProbabilityRNA virusesMutation rateDynamical systems theoryFitness landscapeMutantBiologyVirus ReplicationGenomeModels BiologicalGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesBifurcations0302 clinical medicineMutation RateSingle-peak fitness landscapeError thresholdDynamical systemsReplication modesDifferentiable dynamical systemsEvolutionary dynamics51 - MatemàtiquesGenetics51General Immunology and MicrobiologyModels GeneticApplied MathematicsRNA:Matemàtiques i estadística [Àrees temàtiques de la UPC]General MedicineMutation AccumulationSistemes dinàmics diferenciables030104 developmental biologyViral replicationMutagenesisModeling and SimulationMatemàtiquesGeneral Agricultural and Biological Sciences030217 neurology & neurosurgery
researchProduct

Imbalance of immunological synapse-kinapse states reflects tumor escape to immunity in glioblastoma

2018

Since the proper activation of T cells requires the physical interaction with target cells through the formation of immunological synapses (IS), an alteration at this level could be a reason why tumors escape the immune response. As part of their life cycle, it is thought that T cells alternate between a static phase, the IS, and a dynamic phase, the immunological kinapse (IK), depending on high or low antigen sensing. Our investigation performed in tissue samples of human glioma shows that T cells are able to establish synapsing interactions not only with glioma tumorigenic cells, but also with stromal myeloid cells. Particularly, the IS displaying a T cell receptor-rich (TCR-rich) central…

0301 basic medicineStromal cellCD3 ComplexImmunological SynapsesT-LymphocytesT cellAntigen-Presenting CellsImmunological synapse03 medical and health sciencesImaging Three-DimensionalImmune systemAntigenGliomaTumor MicroenvironmentmedicineHumansMyeloid CellsBrain NeoplasmsChemistryGliomaGeneral Medicinemedicine.diseaseImmunological SynapsesCell biology030104 developmental biologymedicine.anatomical_structureTechnical AdvanceTumor EscapeTumor EscapeGlioblastomaJCI Insight
researchProduct

C3 Drives Inflammatory Skin Carcinogenesis Independently of C5

2021

Nonmelanoma skin cancer such as cutaneous squamous cell carcinoma (cSCC) is the most common form of cancer and can occur as a consequence of DNA damage to the epithelium by UVR or chemical carcinogens. There is growing evidence that the complement system is involved in cancer immune surveillance; however, its role in cSCC remains unclear. Here, we show that complement genes are expressed in tissue from patients with cSCC, and C3 activation fragments are present in cSCC biopsies, indicating complement activation. Using a range of complement-deficient mice in a two-stage mouse model of chemically-induced cSCC, where a subclinical dose of 7,12-dimethylbenz[a]anthracene causes oncogenic mutatio…

0301 basic medicineWT wild typeSkin NeoplasmsComplement receptorComplement Membrane Attack Complexmedicine.disease_causeBiochemistrychemistry.chemical_compoundMice0302 clinical medicineCR complement receptorComplement ActivationSkinMice KnockoutcSCC cutaneous squamous cell carcinomaComplement C5Complement C3Receptors Complement030220 oncology & carcinogenesisCarcinoma Squamous CellDisease ProgressionTumor BiologyOriginal ArticleMAC membrane attack complexSignal TransductionHPV16 human papillomavirus type 16910-Dimethyl-12-benzanthraceneTPA 12-O-tetradecanoylphorbol-13-acetateMice TransgenicDermatologySettore MED/08 - Anatomia Patologica03 medical and health sciencesmedicineAnimalsHumansC3Molecular BiologyReceptor Anaphylatoxin C5aDMBA 712-dimethylbenz[a]anthracenebusiness.industry712-Dimethylbenz[a]anthraceneCancerCell BiologyNeoplasms Experimentalmedicine.diseaseComplement systemDisease Models Animal030104 developmental biologychemistryTumor progressionCancer researchCarcinogensTumor EscapeSkin cancerbusinessCarcinogenesisComplement membrane attack complexSkin carcinogenesis.EC epithelial cell
researchProduct